Is amylin an incretin?

No. Incretins are gut hormones released in response to nutrients that potentiate insulin secretion. Amylin is a beta-cell hormone co-secreted with insulin, with a different receptor and a different mechanism.

What is the area postrema?

A brainstem structure that sits outside the blood-brain barrier, which lets it detect circulating hormones directly. It is central to both satiety signalling and nausea.

Why does native human amylin form amyloid?

Its sequence is prone to aggregation. Clinical analogues substitute proline residues at the aggregation-prone positions to prevent it.

GLP-1 & Incretin Science

What Is an Amylin Receptor Agonist?

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Amylin is a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells. It slows gastric emptying, suppresses glucagon after meals and signals satiety through receptors in the area postrema. Amylin receptor agonists reproduce that signalling, and are being combined with GLP-1 agonists because the two pathways are largely independent.

Key facts

Native hormone: Amylin (islet amyloid polypeptide, IAPP)
Length: 37 amino acids
Co-secreted with: Insulin, from pancreatic beta cells
Principal site of action: Area postrema
Clinical analogues: Pramlintide (short-acting), cagrilintide (long-acting)
Why combined with GLP-1: Largely independent satiety pathways

What amylin does physiologically

Amylin is released alongside insulin in response to a meal and acts as a satiation signal. It slows the rate at which the stomach empties, suppresses inappropriate post-meal glucagon secretion, and acts centrally to reduce meal size. Its actions are complementary to insulin rather than duplicative: insulin manages glucose disposal, amylin manages the rate at which glucose arrives.

Where the receptor is

The amylin receptor is not a single conventional receptor but a complex formed when the calcitonin receptor associates with receptor activity-modifying proteins. The signalling relevant to satiety occurs largely in the area postrema, a circumventricular structure in the brainstem that sits outside the blood-brain barrier and is therefore directly exposed to circulating hormones. That anatomical position is why a peripherally administered amylin analogue can produce a central effect.

Why native amylin could not be used as a drug

Human amylin aggregates readily into amyloid fibrils, which is both a formulation problem and the reason islet amyloid deposits appear in type 2 diabetes. Pramlintide, the first clinical amylin analogue, solved this with proline substitutions borrowed from rat amylin, which does not aggregate. Its short half-life required dosing with each meal. Cagrilintide is the long-acting successor engineered for weekly administration.

Why amylin and GLP-1 combine well

The two hormones reduce food intake through substantially different routes — GLP-1 largely via the hypothalamus and vagal afferents, amylin largely via the area postrema. Because the pathways are not the same, their effects add rather than saturate. This is the mechanistic argument behind CagriSema and amycretin, and it is a different strategy from the incretin multi-agonists, which stay within the glucagon receptor family.

How this fits the broader pipeline

There are now two distinct routes to increasing effect size beyond GLP-1 alone. One adds more incretin-family receptors — GIP, glucagon — as tirzepatide and retatrutide do. The other adds a non-incretin satiety hormone, which is what amylin combinations do. Both work, and they are not mutually exclusive.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is amylin an incretin?: No. Incretins are gut hormones released in response to nutrients that potentiate insulin secretion. Amylin is a beta-cell hormone co-secreted with insulin, with a different receptor and a different mechanism.
What is the area postrema?: A brainstem structure that sits outside the blood-brain barrier, which lets it detect circulating hormones directly. It is central to both satiety signalling and nausea.
Why does native human amylin form amyloid?: Its sequence is prone to aggregation. Clinical analogues substitute proline residues at the aggregation-prone positions to prevent it.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum